DK3783011T5 - Aktivering af bioluminescens via strukturel komplementering - Google Patents

Aktivering af bioluminescens via strukturel komplementering Download PDF

Info

Publication number
DK3783011T5
DK3783011T5 DK20197758.4T DK20197758T DK3783011T5 DK 3783011 T5 DK3783011 T5 DK 3783011T5 DK 20197758 T DK20197758 T DK 20197758T DK 3783011 T5 DK3783011 T5 DK 3783011T5
Authority
DK
Denmark
Prior art keywords
bioluminescence
activation
via structural
structural complementation
complementation
Prior art date
Application number
DK20197758.4T
Other languages
Danish (da)
English (en)
Other versions
DK3783011T3 (da
Inventor
Thomas Kirkland
James Unch
Melanie Dart
Lance P Encell
Mary P Hall
Keith V Wood
Monika G Wood
Marie Schwinn
Brock Binkowski
Hicham Zegzouti
Nidhi Nath
Subhanjan Mondal
Said Goueli
Andrew S Dixon
Poncho Meisenheimer
Dileep K Pulukkunat
Matthew B Robers
Thomas Machleidt
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Application granted granted Critical
Publication of DK3783011T3 publication Critical patent/DK3783011T3/da
Publication of DK3783011T5 publication Critical patent/DK3783011T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0283—Price estimation or determination
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/06—Buying, selling or leasing transactions
    • G06Q30/0601—Electronic shopping [e-shopping]
    • G06Q30/0631—Recommending goods or services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/02—Services making use of location information
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30—Services specially adapted for particular environments, situations or purposes
    • H04W4/35—Services specially adapted for particular environments, situations or purposes for the management of goods or merchandise
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30—Services specially adapted for particular environments, situations or purposes
    • H04W4/38—Services specially adapted for particular environments, situations or purposes for collecting sensor information
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Finance (AREA)
  • Development Economics (AREA)
  • Accounting & Taxation (AREA)
  • General Engineering & Computer Science (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Strategic Management (AREA)
  • Signal Processing (AREA)
  • General Business, Economics & Management (AREA)
  • Theoretical Computer Science (AREA)
  • Economics (AREA)
  • Marketing (AREA)
  • Veterinary Medicine (AREA)
DK20197758.4T 2013-03-15 2014-03-13 Aktivering af bioluminescens via strukturel komplementering DK3783011T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791549P 2013-03-15 2013-03-15
EP14769752.8A EP2970412B1 (en) 2013-03-15 2014-03-13 Activation of bioluminescence by structural complementation

Publications (2)

Publication Number Publication Date
DK3783011T3 DK3783011T3 (da) 2022-10-17
DK3783011T5 true DK3783011T5 (da) 2024-08-19

Family

ID=51581027

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20197758.4T DK3783011T5 (da) 2013-03-15 2014-03-13 Aktivering af bioluminescens via strukturel komplementering
DK14769752.8T DK2970412T5 (da) 2013-03-15 2014-03-13 Aktivering af bioluminescens via strukturel komplementering

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14769752.8T DK2970412T5 (da) 2013-03-15 2014-03-13 Aktivering af bioluminescens via strukturel komplementering

Country Status (15)

Country Link
US (11) US9797889B2 (enExample)
EP (4) EP3783011B1 (enExample)
JP (4) JP6654557B2 (enExample)
KR (3) KR102675860B1 (enExample)
CN (2) CN105143249A (enExample)
AU (3) AU2014236949C1 (enExample)
BR (1) BR112015023394B8 (enExample)
CA (3) CA3249512A1 (enExample)
DK (2) DK3783011T5 (enExample)
ES (2) ES2929362T3 (enExample)
IL (3) IL286816B (enExample)
PL (2) PL2970412T3 (enExample)
PT (2) PT3783011T (enExample)
SG (2) SG11201507306VA (enExample)
WO (1) WO2014151736A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014236949C1 (en) 2013-03-15 2018-11-29 Promega Corporation Activation of bioluminescence by structural complementation
US11365402B2 (en) 2014-09-12 2022-06-21 Promega Corporation Internal protein tags
EP4219736A1 (en) * 2014-09-12 2023-08-02 Promega Corporation Internal protein tags
EP4455668A3 (en) 2015-02-05 2025-02-19 Promega Corporation Luciferase-based thermal shift assays
US10634680B2 (en) 2016-04-26 2020-04-28 University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
AU2017345560C1 (en) 2016-10-20 2025-04-17 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
EP3395803A1 (en) 2017-04-28 2018-10-31 Institut Pasteur Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins
CA3022981C (en) * 2017-11-01 2025-05-06 Queen's University At Kingston HIPPO BIOLUMINOUS TRAIL BIOSENSOR
WO2019164402A1 (en) * 2018-02-26 2019-08-29 Technische Universiteit Eindhoven Bioluminescent biosensor for detecting and quantifying biomolecules
EP4140991B1 (en) 2018-06-01 2024-05-15 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes
EP3807419A4 (en) * 2018-06-12 2022-09-07 Promega Corporation MULTIPLE LUCIFERASE
US10962538B2 (en) 2018-06-14 2021-03-30 The Trustees Of Columbia University In The City Of New York Assays using arrestin recruitment and unmodified receptors
IL318819A (en) 2018-10-03 2025-04-01 Promega Corp Compounds and methods for stabilizing cholinetyrazine and its derivatives
WO2020113036A2 (en) 2018-11-28 2020-06-04 Promega Corporation Reactive peptide labeling
EP3891503A2 (en) 2018-12-04 2021-10-13 Promega Corporation Broad spectrum gpcr binding agents
US11913944B2 (en) 2019-03-20 2024-02-27 Promega Corporation Photoaffinity probes
AU2020272037B2 (en) * 2019-04-10 2025-11-27 Promega Corporation Compositions and methods for analyte detection using bioluminescence
US11360096B2 (en) 2019-05-16 2022-06-14 Duke University Complex BRET technique for measuring biological interactions
CN114450326B (zh) 2019-06-24 2025-02-11 普罗美加公司 用于将生物分子递送到细胞中的改性聚胺聚合物
DE102019127894B4 (de) * 2019-10-16 2022-05-12 Sensor-Instruments Entwicklungs- Und Vertriebs-Gmbh Produktkennzeichnungssystem und verfahren zur kennzeichnung eines produkts
US20230031446A1 (en) * 2019-11-22 2023-02-02 The Regents Of The University Of California Split-enzyme system to detect specific dna in living cells
IL293204B1 (en) 2019-11-27 2026-08-01 Promega Corp Multipartite luciferase peptides and polypeptides
WO2021119149A1 (en) 2019-12-10 2021-06-17 Promega Corporation Compositions and methods for bioluminescent detection using multifunctional probes
EP4127148A1 (en) 2020-03-25 2023-02-08 Erasmus University Rotterdam Medical Center Reporter system for radionuclide imaging
US20230257726A1 (en) * 2020-05-11 2023-08-17 Chan Zuckerberg Biohub, Inc. Ace2 compositions and methods
JP7677997B2 (ja) 2020-05-22 2025-05-15 プロメガ コーポレイション キナーゼターゲットエンゲージメントの増強
WO2022047186A1 (en) 2020-08-28 2022-03-03 Promega Corporation Target engagement assay for ras proteins
EP4337646A4 (en) 2021-05-13 2025-05-21 Promega Corporation BIOLUMINESCENT DETECTION OF DNA SYNTHESIS
US20240252689A1 (en) * 2021-05-18 2024-08-01 The Board Of Regents Of The University Of Texas System Poly-adp ribose (par) tracker optimized split-protein reassembly par detection reagents
US20240132859A1 (en) 2022-05-04 2024-04-25 Promega Corporation Modified dehalogenase with extended surface loop regions
WO2023215514A2 (en) 2022-05-04 2023-11-09 Promega Corporation Bioluminescence-triggered photocatalytic labeling
JP2025516354A (ja) 2022-05-04 2025-05-27 プロメガ コーポレイション スプリット修飾デハロゲナーゼバリアント
EP4519290A1 (en) 2022-05-04 2025-03-12 Promega Corporation Circularly permuted dehalogenase variants
WO2024151471A1 (en) 2023-01-09 2024-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-throughput assay based on ligand-biased structural dynamics response
EP4700040A1 (en) * 2023-04-21 2026-02-25 Shenzhen Loggene Life Science & Technology Co., Ltd. Peptide and luminescent complex containing same
CN121794397A (zh) * 2023-05-04 2026-04-03 普洛麦格公司 用于双模态标记的基于互补性的标签和报告基因
WO2025064581A1 (en) * 2023-09-18 2025-03-27 The Brigham And Women’S Hospital, Inc. Biosensor platform for the rapid detection of analytes
WO2025158412A1 (en) 2024-01-26 2025-07-31 Biohaven Therapeutics Ltd. BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS
WO2026008850A1 (en) 2024-07-04 2026-01-08 Insempra Gmbh Linear nucleic acid templates for high-efficient cell-free protein expression
WO2026008852A2 (en) 2024-07-04 2026-01-08 Insempra Gmbh Optimized media for highly efficient cell-free protein expression systems

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5756688A (en) 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
KR950703582A (ko) 1992-10-14 1995-09-20 조이스 이. 마임스 킬레이트화 중합체(chelating polymers)
GB9503969D0 (en) 1995-02-28 1995-04-19 Sams Bernard Incrementing mechanism
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US5879739A (en) 1997-02-20 1999-03-09 Tower Semiconductor Ltd. Batch process for forming metal plugs in a dielectric layer of a semiconductor wafer
EP1156103B1 (en) * 2000-04-26 2010-08-11 Chisso Corporation Oplophorus luciferase
JP4613441B2 (ja) * 2000-04-26 2011-01-19 チッソ株式会社 新規ルシフェラーゼおよび発光蛋白質
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7008642B1 (en) 2001-02-12 2006-03-07 Advanced Cardiovascular Systems, Inc. Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
US7195884B2 (en) 2002-07-19 2007-03-27 Promega Corp. Methods and kits for transferases
US20040115814A1 (en) * 2002-09-30 2004-06-17 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
US7237811B1 (en) * 2005-04-20 2007-07-03 Lawrence Barry G Casement window latch assembly
EP1931787A4 (en) 2005-09-30 2010-10-20 Univ Montana State SYSTEM FOR DETECTING PROTEIN-PROTEIN INTERACTIONS
US7601517B2 (en) 2006-01-10 2009-10-13 Stanford University Split protein self complementing fragments, systems, and methods of use thereof
US20130332133A1 (en) 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
US20090075313A1 (en) 2007-05-04 2009-03-19 Stanford University Split protein fragments, split protein systems, methods of making split protein systems, and methods of using split protein systems
EP2210104A4 (en) 2007-11-01 2011-02-23 Univ Arizona State CELL-FREE PROCEDURE FOR DETECTING PROTEIN-LIGAND INTERACTIONS
US20100272675A1 (en) * 2007-11-15 2010-10-28 Endocyte, Inc. Method of administering conjugates
GB2479847B (en) 2009-02-09 2014-02-19 Jnc Corp Coelenterazine analogs and manufacturing method thereof
WO2010119721A1 (ja) 2009-04-17 2010-10-21 独立行政法人産業技術総合研究所 超高輝度で安定な人工生物発光酵素
ES2795287T3 (es) 2009-05-01 2020-11-23 Promega Corp Luciferasas de Oplophorus sintéticas con mayor emisión de luz
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
CN103443121B (zh) * 2010-11-02 2016-04-20 普罗梅加公司 新型腔肠素底物及其使用方法
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US10024862B2 (en) * 2012-12-12 2018-07-17 Promega Corporation Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer
AU2014236949C1 (en) 2013-03-15 2018-11-29 Promega Corporation Activation of bioluminescence by structural complementation
EP4219736A1 (en) * 2014-09-12 2023-08-02 Promega Corporation Internal protein tags

Also Published As

Publication number Publication date
CA2906063A1 (en) 2014-09-25
US20200292534A1 (en) 2020-09-17
AU2020213288A1 (en) 2020-08-27
IL273989B (en) 2021-10-31
JP2024167207A (ja) 2024-12-03
AU2014236949C1 (en) 2018-11-29
CA3249512A1 (en) 2026-03-02
IL286816B (en) 2022-09-01
ES2926463T3 (es) 2022-10-26
JP7532562B2 (ja) 2024-08-13
JP7843318B2 (ja) 2026-04-09
KR102675860B1 (ko) 2024-06-20
JP6654557B2 (ja) 2020-02-26
US20180196038A1 (en) 2018-07-12
WO2014151736A1 (en) 2014-09-25
US10107800B2 (en) 2018-10-23
SG11201507306VA (en) 2015-10-29
US20180095074A1 (en) 2018-04-05
EP4169935A1 (en) 2023-04-26
US10288605B2 (en) 2019-05-14
US9797890B2 (en) 2017-10-24
US9869670B2 (en) 2018-01-16
EP2970412B1 (en) 2022-08-10
US12367513B2 (en) 2025-07-22
IL273989A (en) 2020-05-31
US20140363375A1 (en) 2014-12-11
US20250022022A1 (en) 2025-01-16
CN117024548A (zh) 2023-11-10
US20230342826A1 (en) 2023-10-26
US20180313825A1 (en) 2018-11-01
BR112015023394A2 (pt) 2017-11-28
ES2929362T3 (es) 2022-11-28
PL3783011T3 (pl) 2022-11-21
US10184936B2 (en) 2019-01-22
US10648971B2 (en) 2020-05-12
US20140348747A1 (en) 2014-11-27
US11493504B2 (en) 2022-11-08
US20180306782A1 (en) 2018-10-25
AU2018256548A1 (en) 2018-11-22
DK2970412T3 (da) 2022-08-29
JP7280842B2 (ja) 2023-05-24
AU2018256548B2 (en) 2020-05-14
CA3254603A1 (en) 2026-02-19
PT2970412T (pt) 2022-09-13
KR20230079494A (ko) 2023-06-07
PL2970412T3 (pl) 2022-11-14
JP2016519065A (ja) 2016-06-30
BR112015023394B8 (pt) 2023-09-26
JP2023055734A (ja) 2023-04-18
IL240985A0 (en) 2015-11-30
EP3783011B1 (en) 2022-09-21
EP4177261A1 (en) 2023-05-10
CA2906063C (en) 2025-10-07
US12366572B2 (en) 2025-07-22
EP2970412A4 (en) 2016-07-27
EP2970412A1 (en) 2016-01-20
KR20150129721A (ko) 2015-11-20
US20160282340A1 (en) 2016-09-29
DK3783011T3 (da) 2022-10-17
US20250045806A1 (en) 2025-02-06
US9797889B2 (en) 2017-10-24
JP2020097597A (ja) 2020-06-25
PT3783011T (pt) 2022-10-26
AU2020213288B2 (en) 2022-07-07
AU2014236949A1 (en) 2015-09-24
EP3783011A1 (en) 2021-02-24
CN105143249A (zh) 2015-12-09
DK2970412T5 (da) 2024-10-14
IL286816A (en) 2021-10-31
BR112015023394B1 (pt) 2023-08-29
KR20210036422A (ko) 2021-04-02
SG10201601929YA (en) 2016-04-28
AU2014236949B2 (en) 2018-08-02
IL240985B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
IL286816A (en) Activation of biological light emission through structural complementation
DK3087183T3 (da) Modulation af angiopoietin-3-lignende ekspression
DK2845905T3 (da) Fremstilling af oligosaccharider
DK3057964T3 (da) Selektivt substituerede quinolinforbindelser
BR112015016219A2 (pt) alto - falante
DK3336106T3 (da) Anti-fcrh5-antistoffer
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK2961388T3 (da) Kombinationer af lægemidler
DK2965026T3 (da) Generering af slushice
DK3054782T3 (da) Fremgangsmåde til tørring af biomasse
PT2953948T (pt) Antagonistas de integrina fluorada
DK3063264T3 (da) Tørring af mikroorganismer
DK3068800T3 (da) FcRn-specifikke antistoffer
DK3016612T3 (da) Forbedringer af dyredetekteringssystemer
HUE037417T2 (hu) Szubsztituált imidazopiridazinok
EP2945942A4 (en) Voriconazole IMMUNOASSAY
DK3065774T3 (da) Anti-CCL17-antistoffer
DK3008213T3 (da) Detektion af protein-til-protein-interaktioner
EP2987486A4 (en) MITOCHONDRIENAKTIVATOR
FI20145719A7 (fi) Vaimennin
ES1098808Y (es) Juguete-instrumento de muneco bailarin
ES1086233Y (es) Soporte ecologico dispensador de ceniceros
UA26764S (uk) Пневмогідравлічний підсилювач зчеплення
DE202013004317U8 (de) Bergehilfe
CO6990072U1 (es) Artículo de interacción médico-paciente